188 Real-world data on the use of certolizumab pegol for the treatment of axial spondyloarthritis in clinical practice in Europe: 24-week interim results from a prospective non-interventional cohort study
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.